Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A. Olsen, Eric C. Vonderheid, Sean Whittaker et al.|Journal of Clinical Oncology|2011Cited by 657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Tatyana Feldman et al.|The Lancet|2017Cited by 580
Non-Hodgkin’s LymphomasAndrew D. Zelenetz, Furhan Yunus, Jeremy S. Abramson et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 329
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A. Olsen, Julia Scarisbrick, Sean Whittaker et al.|Blood|2021Cited by 170
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016Steven M. Horwitz, Pierluigi Porcu, Andrew D. Zelenetz et al.|Journal of the National Comprehensive Cancer Network|2016Cited by 141